Contributors: Department of Epidemiology and Biostatistics; University of California; Stellenbosch University; Centre for Invasion Biology; Oak Ridge Associated Universities (Ashley Golden); Instituto de Salud Global - Institute For Global Health Barcelona (ISGlobal); Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science; La Trobe University; Laboratoire d épidémiologie des rayonnements ionisants (IRSN/PSE-SANTE/SESANE/LEPID); Service de recherche sur les effets biologiques et Sanitaires des rayonnements ionisants (IRSN/PSE-SANTE/SESANE); Institut de Radioprotection et de Sûreté Nucléaire (IRSN)-Institut de Radioprotection et de Sûreté Nucléaire (IRSN); Cancer Care Ontario; NASA Ames Research Center (ARC); Department of Radiation Protection and Health; Bundesamt für Strahlenschutz - Federal Office for Radiation Protection (BfS); Colorado School of Public Health; National Institute for Occupational Safety and Health Cincinnati (NIOSH); Centers for Disease Control and Prevention (CDC); National Institute for Occupational Safety and Health (NIOSH); International Agency for Research on Cancer (IARC); Radiation Protection Institute (SURO); The University of New Mexico Albuquerque; New Mexico Consortium (NMC); Pôle Santé Environnement - Direction Santé (IRSN/PSE-SANTE); Institut de Radioprotection et de Sûreté Nucléaire (IRSN); Oak Ridge Center for Risk Analysis (Oak Ridge Center for Risk Analysis); Clarendon Laboratory Oxford; University of Oxford; Vanderbilt Epidemiology Center, Institute for Medicine and Public Health; Vanderbilt University School of Medicine Nashville; National Council on Radiation Protection and Measurements (Bethesda) (NCRP); Memorial Sloane Kettering Cancer Center New York; Great Ormond Street Institute of Child Health (UCL); University College of London London (UCL); Vanderbilt University Nashville; Fibrosis Laboratory, Liver Group; Newcastle University Newcastle; Easterly Scientific, Knoxville, Tennessee (Easterly Scientific); Oak Ridge Natl Lab, Biosci Div; US Environmental Protection Agency (EPA); The work relating to PUMA (Richardson was supported by the Centers for Disease Control and Prevention (CDC, R03 OH010946). The construction of the French cohort was partially supported by the Institute for Radiological Protection and Nuclear Safety (IRSN). IRSN thanks ORANO for its cooperation in the elaboration of the French cohort. For the U.S. contribution, funding was provided by the National Institute for Occupational Safety and Health. Dr. Zablotska’s work was funded and supported by the CDC in association with the National Institute for Occupational Safety and Health (NIOSH) Grant (R21OH011452). For the Czech cohort, funding was provided by the National Radiation Protection Institute (SURO), grant MV-25972-2/OBV. Work on the Ontario cohort was funded by the Canadian Nuclear Safety Commission, the Ontario Ministry of Labor, and the Canadian Cancer Society. The work related to the CFCS study (Zablotska was funded by National Cancer Institute (NCI) and National Institutes of Health (NIH), Award No. R01CA197422 (Principal Investigator: LBZ). Calculation of dose conversion coefficients (DCCs) was funded by an intramural program of the Division of Cancer Epidemiology and Genetics, NCI/NIH. The studies reported by Ashley Golden were performed as part of the National Council on Radiation Protection and Measurements Million Person Study acknowledging the financial support for MPS-related science from NASA grants # 80NSSC17M0016 and 80NSSC19M0161 , U.S. DOE grants # DE-AU0000042 and DE-AU0000046 , Naval Sea Systems Command contract # N00024-17-C-4322 , CDC grant # 5NUE1EH001315 , and the U.S. NRC (grant # NRC-HQ-60-14-G-0011).; Taylor and Francis; PUMA
نبذة مختصرة : International audience ; Epidemiological studies of occupational, medical, and environmental exposures have provided important information on lung cancer risk and how those risks might depend on the type of exposure, dose rate, and other potential modifying factors such as sex and age of the exposed. Analyses of data from underground miner cohorts and residential case-control studies provide convincing evidence that radon is a leading cause of lung cancer. For low-LET radiation, risk models derived from results from the Lifespan Study of Japanese atomic bomb survivors suggest that for acute exposures, lifetime attributable risks for lung cancer are greater than for other specific cancer sites and are substantially larger for females than males. However, for protracted and fractionated exposures other than from radon, results from epidemiological studies are seemingly often contradictory.This report includes summaries of oral presentations during a symposium on radiogenic lung cancer risk given by a panel of experts on October 5 during the Radiation Research Society’s 67th annual meeting. This session included presentations on: 1) the largest pooled study of male uranium miners (PUMA) exposed to radon; 2) the most recent analysis of the Canadian Fluoroscopy cohort featuring state-of-the-art dosimetry for radiation exposures associated with frequent medical diagnostic procedures; 3) an update from the Million Person Study on risks from fractionated occupational exposures, and 4) studies of second primary malignancies – including lung cancer – in patients who had been treated for thyroid cancer.
Processing Request
No Comments.